Nikolaos Diamantis
YOU?
Author Swipe
View article: Summation formulas for Hurwitz class numbers and other mock modular coefficients
Summation formulas for Hurwitz class numbers and other mock modular coefficients Open
We prove a formula for weighted sums of the first $n$ coefficients of mock modular forms of moderate growth and apply it to Hurwitz class numbers and coefficients of negative half integral weight Eisenstein series, which take the form of c…
View article: A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer
A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer Open
Fewer than 50% of metastatic deficient mismatch repair (dMMR) colorectal cancer (CRC) patients respond to immune checkpoint inhibition (ICI). Identifying and expanding this patient population remains a pressing clinical need. Here, we repo…
View article: Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator
Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator Open
Aims Fluoropyrimidine chemotherapy is important for treatment of many solid tumours but is associated with cardiotoxicity. The relationship of fluoropyrimidine‐associated cardiotoxicity (FAC) with conventional cardiovascular (CV) risk fact…
View article: Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry Open
In this propensity-score matched analysis, previous ICI therapy did not worsen and potentially improved COVID-19 outcomes in patients with cancer.
View article: Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies
Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies Open
There is an evolving landscape of systemic combination regimens for patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). In this review, we provide a comprehensive outline of the existing clin…
View article: Ensuring no patient is lost along the way – a single‐centre experience of the clinical genetics referral pathways for Lynch syndrome
Ensuring no patient is lost along the way – a single‐centre experience of the clinical genetics referral pathways for Lynch syndrome Open
Lynch syndrome (LS), caused by heterozygous germline mutation in one of the key mismatch repair (MMR) genes, is the primary cause of inherited colorectal cancer (CRC). LS also increases susceptibility to several other cancers. It is estima…
View article: Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer Open
PURPOSE Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included …
View article: COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry Open
Background Fifteen percent of patients with cancer experience symptomatic sequelae, which impair post–COVID-19 outcomes. In this study, we investigated whether a proinflammatory status is associated with the development of COVID-19 sequela…
View article: Time-Dependent COVID-19 Mortality in Patients With Cancer
Time-Dependent COVID-19 Mortality in Patients With Cancer Open
The findings of this registry-based study suggest that mortality in patients with cancer diagnosed with COVID-19 has improved in Europe; this improvement may be associated with earlier diagnosis, improved management, and dynamic changes in…
View article: Dynamics of string-like states of a hole in a quantum antiferromagnet: a diagrammatic Monte Carlo simulation
Dynamics of string-like states of a hole in a quantum antiferromagnet: a diagrammatic Monte Carlo simulation Open
The dynamics of a hole motion in a quantum antiferromagnet has been studied in the past three decades because of its relationship to models related to superconductivity in cuprates. The same problem has received significant attention becau…
View article: Providing an acute oncology service during the COVID-19 pandemic
Providing an acute oncology service during the COVID-19 pandemic Open
The COVID-19 pandemic has led to adaptations being made to all aspects of the NHS, including general practice, acute medical specialties and oncology. This has presented unique challenges to acute oncology services (AOSs) in how to provide…
View article: Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score Open
Background Patients with cancer are particularly susceptible to SARS-CoV-2 infection. The systemic inflammatory response is a pathogenic mechanism shared by cancer progression and COVID-19. We investigated systemic inflammation as a driver…
View article: Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective Open
Background:Specialist palliative care team (SPCT) involvement has been shown to improve symptom control and end-of-life care for patients with cancer, but little is known as to how these have been impacted by the COVID-19 pandemic. Here, w…
View article: COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry Open
Background: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients. Methods: W…
View article: Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective Open
Background: Specialist palliative care team (SPCT) involvement has been shown to improve symptom control and end-of-life care for patients with cancer, but little is known as to how these have been impacted by the COVID-19 pandemic. Here, …
View article: A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials
A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials Open
This is the first study to demonstrate the clinical significance of baseline hypoalbuminaemia and hyponatraemia, which are predictors of development of other EAs in phase I patients. Grade III/IV EAs are adverse prognostic factors of OS in…
View article: Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials
Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials Open
We describe the outcome of the largest cohort of AYA patients treated in phase I trials. A subgroup of these patients demonstrates benefit, with several durable responses beyond 2 years. A sizeable proportion of AYA patients have cancer sy…